The Experts below are selected from a list of 297 Experts worldwide ranked by ideXlab platform
Olivier Glehen - One of the best experts on this subject based on the ideXlab platform.
-
peritoneal carcinomatosis of Urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy hipec an international registry of 36 patients
Annals of Surgical Oncology, 2018Co-Authors: Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goere, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier GlehenAbstract:Peritoneal carcinomatosis or pseudomyxoma peritonei from Urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of Urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. A prospective multicenter international database was retrospectively searched to identify all patients with Urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4–30.5, p < 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications. CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of Urachus origin, especially when complete CRS is achieved.
-
peritoneal carcinomatosis of Urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy hipec an international registry of 36 patients
Annals of Surgical Oncology, 2018Co-Authors: Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goere, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier GlehenAbstract:Purpose Peritoneal carcinomatosis or pseudomyxoma peritonei from Urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of Urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment.
Frederic Mercier - One of the best experts on this subject based on the ideXlab platform.
-
peritoneal carcinomatosis of Urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy hipec an international registry of 36 patients
Annals of Surgical Oncology, 2018Co-Authors: Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goere, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier GlehenAbstract:Peritoneal carcinomatosis or pseudomyxoma peritonei from Urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of Urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. A prospective multicenter international database was retrospectively searched to identify all patients with Urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4–30.5, p < 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications. CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of Urachus origin, especially when complete CRS is achieved.
-
peritoneal carcinomatosis of Urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy hipec an international registry of 36 patients
Annals of Surgical Oncology, 2018Co-Authors: Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goere, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier GlehenAbstract:Purpose Peritoneal carcinomatosis or pseudomyxoma peritonei from Urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of Urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment.
Aaron M. Udager - One of the best experts on this subject based on the ideXlab platform.
-
Glandular Tumors of the Urachus and Urinary Bladder: A Practical Overview of a Broad Differential Diagnosis.
Archives of pathology & laboratory medicine, 2018Co-Authors: Alexander S. Taylor, Rohit Mehra, Aaron M. UdagerAbstract:Primary glandular tumors of the Urachus and urinary bladder are an intriguing group of clinically and morphologically diverse neoplasms for which there have been recent refinements in diagnostic subclassification and advances in molecular pathology. In addition, the Urachus and urinary bladder may be secondarily involved by tumors with glandular differentiation that demonstrate remarkable morphologic, immunophenotypic, and molecular overlap. Thus, surgical pathologists need to be aware of the broad differential diagnosis of glandular tumors that involve the Urachus and urinary bladder and have a practical diagnostic framework to evaluate these lesions in routine clinical practice. In this review, we summarize the salient clinical, morphologic, immunohistochemical, and molecular features of glandular tumors of the Urachus and urinary bladder, including mucinous cystic tumors of the Urachus, noncystic urachal adenocarcinomas, urothelial carcinomas with glandular or pseudoglandular features, primary urinary bladder adenocarcinomas, and Mullerian-type carcinomas, highlighting the strengths and limitations of various diagnostic features and ancillary tests, as well as the need for close clinical and radiographic correlation.
Marie Victoire Sénat - One of the best experts on this subject based on the ideXlab platform.
-
Prenatal diagnosis of a patent Urachus cyst with the use of 2D, 3D, 4D ultrasound and fetal magnetic resonance imaging
Fetal Diagnosis and Therapy, 2009Co-Authors: F Fuchs, A. E. Mas, Michel Mabille, Olivier Picone, René Frydman, Jean-marc Levaillant, Marie Victoire SénatAbstract:Patent Urachus cyst is a rare umbilical anomaly, which is poorly detected prenatally and frequently confounded with pseudo bladder exstrophy or omphalocele. A 27-year-old woman was referred to our prenatal diagnosis centre at 18 weeks of gestation after diagnosis of a megabladder and 2 umbilical cord cysts. Subsequent 2D, 3D and 4D ultrasound examinations and fetal magnetic resonance imaging (MRI) revealed a typical umbilical cyst and an extra-abdominal cyst, communicating with the vertex of the fetal bladder through a small channel that increased in size when the fetus voided urine. Termination of pregnancy occured at 31 weeks because of associated cerebral septal agenesis, and autopsy confirmed the prenatal diagnosis of Urachus cyst. Few cases of Urachus cyst diagnosed prenatally are reported in literature, but none were associated with other extra-abdominal disorders and none used 3D, 4D and fetal MRI. Our case illustrated the efficiency in prenatal diagnosis of 3D and 4D ultrasound examinations. This could help pediatrician surgeons to explain to a couple about neonatal surgical repair and plastic reconstruction in the prenatal period.
Edward A Levine - One of the best experts on this subject based on the ideXlab platform.
-
peritoneal carcinomatosis of Urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy hipec an international registry of 36 patients
Annals of Surgical Oncology, 2018Co-Authors: Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goere, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier GlehenAbstract:Peritoneal carcinomatosis or pseudomyxoma peritonei from Urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of Urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment. A prospective multicenter international database was retrospectively searched to identify all patients with Urachus tumor and peritoneal metastases who underwent CRS and HIPEC through the Peritoneal Surface Oncology Group International (PSOGI). Postoperative complications, long-term results, and principal prognostic factors were analyzed. The analysis included 36 patients. After median follow-up of 48 months, median overall survival (OS) was 58.5 months. Three- and 5-year OS was 55.4 and 46.2%, respectively. Patients who underwent complete macroscopic CRS had significantly better survival than those treated with incomplete CRS, with median OS not achieved and of 20.1 months, respectively [95% confidence interval (CI) 4.4–30.5, p < 0.001]. There were no postoperative deaths, and 37.9% of patients had major complications. CRS and HIPEC may increase long-term survival in selected patients with peritoneal metastases of Urachus origin, especially when complete CRS is achieved.
-
peritoneal carcinomatosis of Urachus origin treated by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy hipec an international registry of 36 patients
Annals of Surgical Oncology, 2018Co-Authors: Frederic Mercier, Guillaume Passot, Laurent Villeneuve, Edward A Levine, Yutaka Yonemura, Diane Goere, Paul H Sugarbaker, Christelle Marolho, David L Bartlett, Olivier GlehenAbstract:Purpose Peritoneal carcinomatosis or pseudomyxoma peritonei from Urachus is a rare form of presentation, often diagnosed at an advanced state of tumor burden. Because of its rarity, little is known about its natural history, prognosis, or optimal treatment. We searched a large international multicenter database of peritoneal surface disease to identify cases of peritoneal carcinomatosis of Urachus that were treated with cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) at expert centers. The aim is to improve knowledge and understanding of the disease and standardize its treatment.
